houston-biotech
(3)
Phillip Maderia
Phillip Maderia is the Chief Executive Officer of PranaX, a Houston-based regenerative-medicine biotech developing stem cell-derived exosome products at the Levit Green campus in the Texas Medical Center. He joined in March 2025 after four years running Lonza's exosome manufacturing site in Lexington, Massachusetts - the facility Lonza bought from Codiak BioSciences in 2021, where Maderia had previously served as VP of Manufacturing Operations. He is a career biomanufacturing operator with roots at Sanofi Genzyme and LFB-USA and roughly three decades of scale-up experience.
Andrew DeSomma
Andrew DeSomma is the Chief Business Officer of K2bio (K2 BioLabs), a Houston-based hybrid contract research organization that gives early-stage life-science companies the equipment, vivarium, and scientists they could never afford to build alone. A career investor with a 25-plus-year track record across technology, biotech, consumer, and retail, he is the founder and manager of Resolute Investments and previously analyzed companies for crossover hedge funds in the San Francisco Bay Area. A Georgetown graduate who now works from Santa Fe, he sat on K2's board at founding before stepping into the operating seat that turns the lab's science into deals.
Stephen Rubino
Stephen Rubino is the CEO of Sporos Bioventures, a Houston-based biotech that runs cancer drug development as a portfolio rather than a single bet. A Cornell-trained virologist with a Baruch MBA, he spent three decades in business development and commercial roles at Schering-Plough, Novartis, Celyad Oncology and Fortress Biotech before taking the helm at Sporos in 2022, where the lead program is SPR1, a next-generation TEAD inhibitor aimed at hard-to-drug cancers.